• Angiotensin Peptides and SARS-CoV-2 Receptor Binding

  2026-09-12

  Oliveira and colleagues report that naturally occurring angiotensin peptides can increase SARS-CoV-2 spike-protein binding to host receptors, with the strongest effects associated with selected shorter peptides and modifications around tyrosine. The work connects renin–angiotensin system biology with viral receptor engagement, while its binding-focused design calls for cautious interpretation beyond biochemical assays.

• Leucovorin Calcium in Gastric Cancer Assembloids

  2026-09-12

  Explore how Leucovorin Calcium, or calcium folinate, can function as a mechanistic rescue control in patient-derived gastric cancer assembloid assays. This article connects folate biology with tumor–stroma-dependent drug response and provides a framework for interpreting methotrexate rescue data.

• WM-8014: A Practical KAT6A Inhibitor Workflow

  2026-09-11

  WM-8014 combines reversible, competitive acetyl-CoA-site inhibition with a useful KAT6A/KAT6B selectivity window for studying cell-cycle arrest and senescence. This guide translates time-gated CRISPR findings into practical pharmacological workflows for epigenetic and cancer biology research, with assay design and troubleshooting guidance.

• 3-Hydroxybutyrate (BHBA): From Ketosis to Stroke

  2026-09-11

  3-hydroxybutyrate (BHBA) is more than an alternative fuel: it is a ketone body signaling molecule and class I HDAC inhibitor with potential relevance to ferroptosis, neuronal stress, and translational stroke research. This article connects the mechanistic evidence from remote ischemic postconditioning with practical experimental strategy and product selection.

• Carbenoxolone disodium: Practical Workflow Guide

  2026-09-10

  Carbenoxolone disodium is an 11β-hydroxysteroid dehydrogenase inhibitor for controlled studies of glucocorticoid access, corticosterone metabolism, and gap junction communication. It is best used in cell- and tissue-based mechanistic workflows with solvent, viability, and pathway controls, rather than as a validated in vivo efficacy agent or disease treatment.

• Leucovorin Calcium in Tumor Assembloid Translation

  2026-09-10

  Leucovorin Calcium, also known as calcium folinate, can serve as more than a methotrexate rescue reagent. In patient-derived gastric cancer assembloids, it offers a mechanistic control for separating folate-pathway dependence, stromal modulation, and antifolate resistance phenotypes in translational drug research.

• Rifampin as a Transcriptional Control Benchmark

  2026-09-09

  Rifampin is more than a rifamycin antibiotic: it is a mechanistically defined benchmark for bacterial transcription control. This guide connects its DNA-dependent RNA polymerase inhibition to modern assay design and contrasts transcriptional control with the light-gated translational switch reported in recent gene-therapy research.

• LEE011 Succinate: A CDK Inhibitor for Translation

  2026-09-09

  Ribociclib succinate gives translational researchers a selective pharmacological handle on CDK4/6-driven cell-cycle regulation. This thought-leadership analysis connects rigorous cancer-model design with lessons from mechanistic antiviral research, while defining practical boundaries for reproducibility, interpretation, and future validation.

• MEHP, AhR, and Ovarian Follicle Toxicity

  2026-09-08

  The 2024 Biology of Reproduction study identifies aryl hydrocarbon receptor activation as a functional mediator of mono(2-ethylhexyl) phthalate toxicity in mouse ovarian antral follicles. Pharmacological AhR blockade partially restored follicle growth, estrogen production, and estrogen-responsive gene expression, providing a mechanistic framework for reproductive environmental toxicology research.

• Ajugol, Mitophagy, and Chondrocyte Pyroptosis

  2026-09-07

  A 2026 study identifies impaired PINK1/Parkin-dependent mitophagy as a mechanistic link between mitochondrial stress and chondrocyte pyroptosis in acute gouty arthritis. Using computational analyses, human chondrocytes, pharmacological pathway controls, and an MSU-induced mouse model, the authors show that ajugol suppresses PI3K/AKT/mTOR signaling, restores mitochondrial quality control, and limits cartilage inflammation.

• SU5416: Deconvoluting Vascular Signaling

  2026-09-07

  SU5416 (Semaxanib) is more than a VEGFR2 inhibitor: it can serve as a mechanistic probe for separating receptor-driven angiogenesis from oxygen-independent HIF1α signaling. This guide integrates product chemistry, vascular metabolism, assay design, and translational limitations.

• Phenothiazines Boost Macrophage Antibacterial Defense

  2026-09-05

  The 2025 reference study shows that phenothiazines strengthen macrophage control of intracellular bacteria by increasing lysosomal activity, autophagy, and reactive oxygen species accumulation. Its host-directed therapy framework supports mechanistic testing of phenothiazine compounds while emphasizing that immune-cell protection, rather than direct bacterial killing, is the central therapeutic concept.

• IRG1–Itaconic Acid Control of TBK1 Signaling

  2026-09-05

  Chai et al. identify an IRG1–itaconic acid feedback pathway that restrains TBK1-driven type I interferon production through alkylation of TBK1 at Cys605 and disruption of its dimerization. The study also introduces ITA-5 and ITA-9 as itaconic acid-based candidate inhibitors, offering a mechanistic framework for limiting excessive interferon signaling while highlighting important questions about specificity, context, and translational maturity.

• AP1903: Tuning FKBP Assays by Expression Level

  2026-09-04

  AP1903 is an FKBP-binding ligand for controlled protein activation, apoptosis pathway research, and conditional cell ablation. This article explains how pairing chemical dimerization with calibrated transgene expression can make FKBP assays more interpretable.

• Hydroxytyrosol: Mechanisms and Research Use

  2026-09-04

  Hydroxytyrosol is an olive-derived phenolic antioxidant bioactive compound studied for oxidative stress modulation, inflammatory signaling, and cardiovascular health research. Cellular evidence links hydroxytyrosol with lower reactive oxygen species and lipid peroxidation, anti-inflammatory macrophage changes, and increased cholesterol efflux, but these findings do not establish clinical treatment efficacy.

7941 records 1/530 page Next 12345 下5页 Last page